CD274 and cancer: Prednisone equivalent ≥10 mg daily for the symptomatic treatment of cancer-related symptoms at the time of initiation or during anti-PD-(L)1 blockade treatment was associated with significantly poorer outcomes than for patients who did not receive corticosteroids or those who received them to manage irAEs.